Massalee Rachel, Cao Xuefang
Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland Baltimore School of Medicine, Baltimore, MD, United States.
Department of Microbiology and Immunology, University of Maryland Baltimore School of Medicine, Baltimore, MD, United States.
Front Pharmacol. 2024 Jan 9;14:1325050. doi: 10.3389/fphar.2023.1325050. eCollection 2023.
Beta-adrenergic receptor signaling regulates cellular processes associated with facilitating tumor cell proliferation and dampening anti-tumor immune response. These cellular processes may lead to compromised tumor control and cancer progression. Based on this ramification, Beta-blockers (BBs) have emerged as a potential treatment by inhibiting beta-adrenergic receptor signaling. This review aimed to investigate the relationship between the use of BBs and tumor progression and treatment response. Therefore, the authors explored several aspects: the potential synergistic relationship of BBs with chemotherapy and immunotherapy in enhancing the effectiveness of chemotherapeutic and immunotherapeutic treatments and their role in boosting endogenous immunity. Further, this review explores the distinctions between the major types of BBs: Non-selective Beta Blockers (NSBBs) and Selective Beta Blockers (SBBs), and their contributions to combinatory cancer treatment. In this review, we presented a perspective interpretation of research findings and future directions. Overall, this review discusses the potential and challenge that BBs present in improving the effectiveness and outcome of cancer treatment.
β-肾上腺素能受体信号传导调节与促进肿瘤细胞增殖和抑制抗肿瘤免疫反应相关的细胞过程。这些细胞过程可能导致肿瘤控制受损和癌症进展。基于这一影响，β受体阻滞剂（BBs）已成为一种通过抑制β-肾上腺素能受体信号传导的潜在治疗方法。本综述旨在研究使用BBs与肿瘤进展和治疗反应之间的关系。因此，作者探讨了几个方面：BBs与化疗和免疫疗法在提高化疗和免疫治疗效果方面的潜在协同关系，以及它们在增强内源性免疫方面的作用。此外，本综述探讨了主要类型的BBs之间的区别：非选择性β受体阻滞剂（NSBBs）和选择性β受体阻滞剂（SBBs），以及它们在联合癌症治疗中的作用。在本综述中，我们对研究结果和未来方向进行了前瞻性解读。总体而言，本综述讨论了BBs在提高癌症治疗效果和结果方面的潜力和挑战。
